Tag: Incannex Health - Psychedelic Alpha

Introducing Pα+: learn more and subscribe today.

Read more about the article Incannex Engages Curia to Scale-up Manufacture of cGMP IHL-216A

Incannex Engages Curia to Scale-up Manufacture of cGMP IHL-216A

Post published:August 3, 2022
Post category:Press Release

Read more about the article Incannex Healthcare Quarterly Activities Report and Appendix 4C Cash Flow Statement

Incannex Healthcare Quarterly Activities Report and Appendix 4C Cash Flow Statement

Post published:July 28, 2022
Post category:Press Release

Read more about the article Incannex Receives Ethics Approval to Commence Phase 1 Clinical Trial of Multi-Use Anti-Inflammatory Drug IHL-675A

Incannex Receives Ethics Approval to Commence Phase 1 Clinical Trial of Multi-Use Anti-Inflammatory Drug IHL-675A

Post published:July 23, 2022
Post category:Press Release

Read more about the article Incannex to Present at the H.C. Wainwright First Annual Mental Health Conference

Incannex to Present at the H.C. Wainwright First Annual Mental Health Conference

Post published:June 27, 2022
Post category:Press Release

Read more about the article Incannex announces positive results from phase 2 clinical trial investigating the effect of IHL-42X for treatment of obstructive sleep apnoea

Incannex announces positive results from phase 2 clinical trial investigating the effect of IHL-42X for treatment of obstructive sleep apnoea

Post published:June 3, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.